Effect of Bortezomib, Daptomycin and Their Combination on Antiproliferation in U266 Multiple Myeloma Cell Line

Multiple myeloma is the second most common hematological malignancy in adults. Although current treatment approaches extend survival to 6 to 10 years in multiple myeloma treatment, most patients relapse. This situation has led to the need for new therapeutic agents in the treatment of multiple myeloma. Daptomycin, a drug molecule isolated from Streotomyces roseosporus and used especially in infections caused by Gram-positive bacteria, has been shown in recent studies to suppress tumor migration and angiogenesis. Bortezomib is a chemotherapy drug currently used in the treatment of multiple myeloma. In this study, we determined the antiproliferative effect of Bortezomib and Daptomycin applications on the U266 multiple myeloma cell line by % cell viability analysis with the XTT method. In addition, we determined the apoptosis levels of U266 multiple myeloma cell lines by flow cytometry. In conclusion, we determined that the combined application of Bortezomib and Daptomycin increased the anticancer effect of Bortezomib alone in U266 multiple myeloma cell lines. In light of the data obtained from this study, we can say that the effect of Daptomycin added to Bortezomib in the treatment of multiple myeloma may contribute significantly to the treatment of the disease.